Targets for medical therapy to limit abdominal aortic aneurysm progression

Current Drug Targets

Volumn 15, Issue 9, 2014, Pages 860-873

  Emeto, Theophilus I ^a   Seto, Sai Wang ^a   Golledge, Jonathan ^a,b  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Abdominal aortic aneurysm; Animal models; Clinical trial; Pharmacotherapy

Indexed keywords

ANTITHROMBOCYTIC AGENT; ACETYLSALICYLIC ACID; ALISKIREN; ALPHA TOCOPHEROL; AMLODIPINE; ATORVASTATIN; BETA CAROTENE; CAPTOPRIL; CELECOXIB; CURCUMIN; CYCLOSPORIN; DOXYCYCLINE; ENALAPRIL; ESTRADIOL; EVEROLIMUS; FASUDIL; FENOFIBRATE; GELATINASE B; INDOMETACIN; LISINOPRIL; LOSARTAN; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRROLIDINE DITHIOCARBAMATE; RAPAMYCIN; SEX HORMONE; SIMVASTATIN; TAMOXIFEN; TICAGRELOR; UNINDEXED DRUG; VALSARTAN;

ANIMAL; AORTIC ANEURYSM, ABDOMINAL; DISEASE COURSE; HUMAN; MOLECULARLY TARGETED THERAPY; PATHOLOGY; ABDOMINAL AORTA ANEURYSM; APOPTOSIS; ARTICLE; BLOOD CLOTTING; CHLAMYDIA; DISEASE SEVERITY; EXTRACELLULAR MATRIX; HYPOXIA; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN DEGRADATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; DISEASE PROGRESSION; HUMANS; MOLECULAR TARGETED THERAPY; PLATELET AGGREGATION INHIBITORS;

EID: 84906899765     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140804155036     Document Type: Review

References (216)

1. Emeto TI, Moxon JV, Biros E, et al. Urocortin 2 is associated with abdominal aortic aneurysm and mediates anti-proliferative effects on vascular smooth muscle cells via corticotrophin releasing factor receptor 2. Clin Sci (Lond) 2014; 126(7): 517-27.
2. Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. aneurysm detection and management (adam) veterans affairs cooperative study group. Ann Intern Med 1997; 126(6): 441-9.
3. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005; 365: 1577-89.
4. Thompson MM. Controlling the expansion of abdominal aortic aneurysms. Br J Surg 2003; 98(8): 897-8.
5. Moxon JV, Parr A, Emeto TI, Walker P, Norman PE, Golledge J. Diagnosis and monitoring of abdominal aortic aneurysm: current status and future prospects. Curr Probl Cardiol 2010; 35(10): 512-48.
6. Participants UKSAT. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346(19): 1445-52.
7. Golledge J, Norman PE. Pathophysiology of abdominal aortic aneurysm relevant to improvements in patients' management. Curr Opin Cardiol 2009; In press.
8. Hughes ML, Fontenelle LJ. A 5-year review of abdominal aortic aneurysms at a VA medical center. Curr Surg 2000; 57(4): 343-5.
9. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58(19): 2020-45.
10. Timaran CH, Veith FJ, Rosero EB, et al. Endovascular aortic aneurysm repair in patients with the highest risk and in-hospital mortality in the United States. Arch Surg 2007; 142(6): 520-4.
11. Brox AC, Filion KB, Zhang X, et al. In-hospital cost of abdominal aortic aneurysm repair in Canada and the United States. Arch Intern Med 2003; 163: 2500-4.
12. Gandhi RH, Irizarry E, Cantor JO, et al. Analysis of elastin crosslinking and the connective tissue matrix of abdominal aortic aneurysms. Surgery 1994; 115(5): 617-20.
13. Lopez-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol 1997; 150(3): 993-1007.
14. Lopez-Candales A, Holmes D, Liao S, Scott M, Wickline S, Thompson R. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol 1997; 150(3): 993-1007.
15. Rowe VL, Stevens SL, Reddick TT, et al. Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human aortas. J Vasc Surg 2000; 31(3): 567-76.
16. Koch AE, Haines GK, Rizzo RJ, et al. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immunemediated response. Am J Pathol 1990; 137(5): 1199-213.
17. Koch A, Kunkel S, Pearce W, et al. Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms. Am J Pathol 1993; 142(5): 1423-31.
18. Kazi M, Thyberg J, Religa P, et al. Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J Vasc Surg 2003; 38(6): 1283-92.
19. Gillum RF. Epidemiology of aortic aneurysm in the United States. J Clin Epidemiol 1995; 48(11): 1289-98.
20. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005; 365(9470): 1577-89.
21. Thompson MM. Controlling the expansion of abdominal aortic aneurysms. Br J Surg 2003; 90(8): 897-8.
22. Carrell TW, Burnand KG, Booth NA, Humphries J, Smith A. Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms. Vascular 2006; 14(1): 9-16.
23. Allison MA, Kwan K, DiTomasso D, Wright CM, Criqui MH. The epidemiology of abdominal aortic diameter. J Vasc Surg 2008; 48(1): 121-7.
24. Lindholt JS. Aneurysmal wall calcification predicts natural history of small abdominal aortic aneurysms. Atherosclerosis 2008; 197(2): 673-8.
25. Parr A, McLaughlin S, McLaughlin M, Golledge J. Aortic calcification and abdominal aortic aneurysm expansion. Atherosclerosis 2009; 202(2): 350.
26. Vega de Céniga M, Gómez R, Estallo L, de la Fuente N, Viviens B, Barba A. Analysis of Expansion Patterns in 4-4.9 cm Abdominal Aortic Aneurysms. Ann Vasc Surg 2008; 22(1): 37-44.
27. Wolf YG, Thomas WS, Brennan FJ, Goff WG, Sise MJ, Bernstein EF. Computed tomography scanning findings associated with rapid expansion of abdominal aortic aneurysms. J Vasc Surg 1994; 20(4): 529-35; discussion 35-8.
28. Satta J, Laara E, Juvonen T. Intraluminal thrombus predicts rupture of an abdominal aortic aneurysm. J Vasc Surg 1996; 23(4): 737-9.
29. Hans SS, Jareunpoon O, Balasubramaniam M, Zelenock GB. Size and location of thrombus in intact and ruptured abdominal aortic aneurysms. J Vasc Surg 2005; 41(4): 584-8.
30. Swedenborg J, Ericksson P. The Intraluminal Thrombus as a Source of Proteolytic Activity. Ann N Y Acad Sci 2006; 1085(The Abdominal Aortic Aneurysm: Genetics, Pathophysiology, and Molecular Biology): 133-8.
31. Golledge J, Iyer V, Jenkins J, Bradshaw B, Cronin O, Walker PJ. Thrombus volume is similar in patients with ruptured and intact abdominal aortic aneurysms. J Vasc Surg 2014; 59(2): 315-20.
32. Vorp DA, Lee PC, Wang DH, et al. Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. J Vasc Surg 2001; 34(2): 291-9.
33. Yan L, Borregaard N, Kjeldsen L, Moses MA. The High Molecular Weight Urinary Matrix Metalloproteinase (MMP) Activity Is a Complex of Gelatinase B/MMP-9 and Neutrophil Gelatinaseassociated Lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276(40): 37258-65.
34. Jagadesham VP, Scott DJ, Carding SR. Abdominal aortic aneurysms: an autoimmune disease?. Trends Mol Med 2008; 14(12): 522-9.
35. Gregory AK, Yin NX, Capella J, Xia S, Newman KM, Tilson MD. Features of autoimmunity in the abdominal aortic aneurysm. Arch Surg 1996; 131(1): 85-8.
36. Bergoeing MP, Thompson RW, Curci JA. Pharmacological targets in the treatment of abdominal aortic aneurysms. Expert Opin Ther Targets 2006; 10(4): 547-59.
37. Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis 2011; 217(1): 57-63.
38. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2004; 24(3): 429-34.
39. Trollope A, Moxon JV, Moran CS, Golledge J. Animal models of abdominal aortic aneurysm and their role in furthering management of human disease. Cardiovasc Pathol 2011; 20(2): 114-23.
40. Moxon JV, Padula MP, Clancy P, et al. Proteomic analysis of intraarterial thrombus secretions reveals a negative association of clusterin and thrombospondin-1 with abdominal aortic aneurysm. Atherosclerosis 2011; 219(2): 432-9.
41. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005; 111(23): 3119-25.
42. Golledge J, Clancy P, Moran C, et al. The novel association of the chemokine CCL22 with abdominal aortic aneurysm. Am J Pathol 2010; 176(5): 2098-106.
43. Seto SW, Krishna SM, Moran CS, Liu D, Golledge J. Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein E deficient mouse model. Clin Sci (Lond). 2014.
44. Moran CS, Jose RJ, Moxon JV, et al. Everolimus limits aortic aneurysm in the apolipoprotein E-deficient mouse by downregulating C-C chemokine receptor 2 positive monocytes. Arterioscler Thromb Vasc Biol 2013; 33(4): 814-21.
45. King VL, Trivedi DB, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006; 26(5): 1137-43.
46. Golledge J, Cullen B, Moran C, Rush C. Efficacy of simvastatin in reducing aortic dilatation in mouse models of abdominal aortic aneurysm. Cardiovasc Drugs Ther 2010; 24(5-6): 373-8.
47. Daugherty A, Rateri DL, Cassis LA. Role of the renin-angiotensin system in the development of abdominal aortic aneurysms in animals and humans. Ann N Y Acad Sci 2006; 1085: 82-91.
48. Golledge J, Cullen B, Rush C, et al. Peroxisome proliferatoractivated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis 2010; 210(1): 51-6.
49. Golledge J. Is there a new target in the renin-angiotensin system for aortic aneurysm therapy? Arterioscler Thromb Vasc Biol 2013; 33(7): 1456-7.
50. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105(11): 1605-12.
51. Emeto TI, Moxon JV, Rush C, Woodward L, Golledge J. Relevance of urocortins to cardiovascular disease. J Mol Cell Cardiol 2011; 51(3): 299-307.
52. Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23(9): 1621-6.
53. Swedenborg J, Mayranpaa MI, Kovanen PT. Mast cells: important players in the orchestrated pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2011; 31(4): 734-40.
54. Railton CJ, Wolpin J, Lam-McCulloch J, Belo SE. Reninangiotensin blockade is associated with increased mortality after vascular surgery. Can J Anaesth 2010; 57(8): 736-44.
55. Tsunemi K, Takai S, Nishimoto M, et al. Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta. Hypertens Res 2002; 25(6): 817-22.
56. Nishimoto M, Takai S, Fukumoto H, et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci 2002; 71(18): 2195-205.
57. Chrysant SG. Vascular remodeling: the role of angiotensinconverting enzyme inhibitors. Am Heart J 1998; 135(2 Pt 2): S21-30.
58. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97(14): 1411-20.
59. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, Thompson RW. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001; 33(5): 1057-64.
60. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001; 134(4): 865-70.
61. Fujiwara Y, Shiraya S, Miyake T, et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med 2008; 22(6): 703-8.
62. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368(9545): 1449-56.
63. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensinconverting enzyme inhibitors and aortic rupture: a populationbased case-control study. Lancet 2006; 368(9536): 659-65.
64. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg 2010; 52(1): 1-4.
65. Lederle FA. Should abdominal aortic aneurysm be managed differently in women? Scand J Surg 2008; 97(2): 125-7.
66. Lederle FA, Johnson GR, Wilson SE. Abdominal aortic aneurysm in women. J Vasc Surg 2001; 34(1): 122-6.
67. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53(3): 605-19.
68. Ailawadi G, Eliason JL, Roelofs KJ, et al. Gender differences in experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2004; 24(11): 2116-22.
69. Martin-McNulty B, Tham DM, da Cunha V, et al. 17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23(9): 1627-32.
70. Grigoryants V, Hannawa KK, Pearce CG, et al. Tamoxifen upregulates catalase production, inhibits vessel wall neutrophil infiltration, and attenuates development of experimental abdominal aortic aneurysms. J Vasc Surg 2005; 41(1): 108-14.
71. Henriques TA, Huang J, D'Souza SS, Daugherty A, Cassis LA. Orchidectomy, but not ovariectomy, regulates angiotensin IIinduced vascular diseases in apolipoprotein E-deficient mice. Endocrinology 2004; 145(8): 3866-72.
72. Allaire E, Forough R, Clowes M, Starcher B, Clowes AW. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 1998; 102(7): 1413-20.
73. Houard X, Touat Z, Ollivier V, et al. Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovasc Res 2009; 82(3): 532-41.
74. Miller FJ, Jr., Sharp WJ, Fang X, Oberley LW, Oberley TD, Weintraub NL. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. Arterioscler Thromb Vasc Biol 2002; 22(4): 560-5.
75. Yajima N, Masuda M, Miyazaki M, Nakajima N, Chien S, Shyy JY. Oxidative stress is involved in the development of experimental abdominal aortic aneurysm: a study of the transcription profile with complementary DNA microarray. J Vasc Surg 2002; 36(2): 379-85.
76. Ricciotti E, FitzGerald GA. Prostaglandins and Inflammation. Arterioscler Thromb Vasc Biol 2011; 31(5): 986-1000.
77. Miyake T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res 2009; 83(3): 436-43.
78. Reilly JM, Miralles M, Wester WN, Sicard GA. Differential expression of prostaglandin E2 and interleukin-6 in occlusive and aneurysmal aortic disease. Surgery 1999; 126(4): 624-7; discussion 7-8.
79. Bayston T, Ramessur S, Reise J, Jones KG, Powell JT. Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Surg 2003; 38(2): 354-9.
80. Holmes DR, Wester W, Thompson RW, Reilly JM. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997; 25(5): 810-5.
81. Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999; 100(1): 48-54.
82. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 2007; 73(1): 227-36.
83. Miralles M, Wester W, Sicard GA, Thompson R, Reilly JM. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 1999; 29(5): 884-92; discussion 92-3.
84. Holmes DR, Petrinec D, Wester W, Thompson RW, Reilly JM. Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res 1996; 63(1): 305-9.
85. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332(7553): 1302-8.
86. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115(12): 1634-42.
87. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr 2005; 25: 151-74.
88. Nakahashi TK, Hoshina K, Tsao PS, et al. Flow loading induces macrophage antioxidative gene expression in experimental aneurysms. Arterioscler Thromb Vasc Biol 2002; 22(12): 2017-22.
89. Gavrila D, Li WG, McCormick ML, et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25(8): 1671-7.
90. Tornwall ME, Virtamo J, Haukka JK, Albanes D, Huttunen JK. Alpha-tocopherol (vitamin E) and beta-carotene supplementation does not affect the risk for large abdominal aortic aneurysm in a controlled trial. Atherosclerosis 2001; 157(1): 167-73.
91. Woods TC, Marks AR. Drug-eluting stents. Annu Rev Med 2004; 55: 169-78.
92. Kirsch AH, Riegelbauer V, Tagwerker A, Rudnicki M, Rosenkranz AR, Eller K. The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. Am J Physiol Renal Physiol 2012; 303(4): F569-75.
93. Lawrence DM, Singh RS, Franklin DP, Carey DJ, Elmore JR. Rapamycin suppresses experimental aortic aneurysm growth. J Vasc Surg 2004; 40(2): 334-8.
94. Dobrin PB, Baumgartner N, Anidjar S, Chejfec G, Mrkvicka R. Inflammatory aspects of experimental aneurysms. Effect of methylprednisolone and cyclosporine. Ann N Y Acad Sci 1996; 800: 74-88.
95. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008; 75(4): 787-809.
96. Chan MM, Huang HI, Fenton MR, Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 1998; 55(12): 1955-62.
97. Leclercq IA, Farrell GC, Sempoux C, dela Pena A, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004; 41(6): 926-34.
98. Parodi FE, Mao D, Ennis TL, Pagano MB, Thompson RW. Oral administration of diferuloylmethane (curcumin) suppresses proinflammatory cytokines and destructive connective tissue remodeling in experimental abdominal aortic aneurysms. Ann Vasc Surg 2006; 20(3): 360-8.
99. Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A, Lopez-Lazaro M. The dark side of curcumin. Int J Cancer 2010; 126(7): 1771-5.
100. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005; 16(6): 624-9.
101. Nomura S, Yoshimura K, Akiyama N, et al. HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins. Eur Surg Res 2005; 37(6): 370-8.
102. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97(12): 1232-5.
103. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109(21 Suppl 1): Ii18-26.
104. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21(11): 1712-9.
105. Nicholls SJ, Cutri B, Worthley SG, et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2005; 25(11): 2416-21.
106. Hartung D, Sarai M, Petrov A, et al. Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. J Nucl Med 2005; 46(12): 2051-6.
107. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005; 241(1): 92-101.
108. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32(1): 21-6.
109. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006; 97(2): 279-80.
110. Kalyanasundaram A, Elmore JR, Manazer JR, et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006; 43(1): 117-24.
111. Evans J, Powell JT, Schwalbe E, Loftus IM, Thompson MM. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg 2007; 34(3): 302-3.
112. Zhang Y, Naggar JC, Welzig CM, et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol 2009; 29(11): 1764-71.
113. Shiraya S, Miyake T, Aoki M, et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2009; 202(1): 34-40.
114. Wang YX, Martin-McNulty B, Huw LY, et al. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis 2002; 162(1): 23-31.
115. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2(5): 205-7.
116. Nagashima H, Aoka Y, Sakomura Y, et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36(1): 158-63.
117. Houdek K, Molacek J, Treska V, et al. Focal histopathological progression of porcine experimental abdominal aortic aneurysm is mitigated by atorvastatin. Int Angiol 2013; 32(3): 291-306.
118. Takahashi K, Matsumoto Y, Do e Z, et al. Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation. PloS one 2013; 8(8): e72558.
119. Krishna SM, Seto SW, Moxon JV, et al. Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am J Pathol 2012; 181(2): 706-18.
120. Schlosser FJ, Tangelder MJ, Verhagen HJ, et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008; 47(6): 1127-33.
121. Mosorin M, Niemela E, Heikkinen J, et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg 2008; 7(4): 578-81.
122. Karrowni W, Dughman S, Hajj GP, Miller FJ, Jr. Statin therapy reduces growth of abdominal aortic aneurysms. J Investig Med 2011; 59(8): 1239-43.
123. Kajimoto K, Miyauchi K, Kasai T, et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009; 206(2): 505-11.
124. Schweitzer M, Mitmaker B, Obrand D, et al. Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms. Vasc Endovascular Surg 2010; 44(2): 116-22.
125. Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA, Hafez H. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 2010; 52(1): 55-61 e2.
126. Ferguson CD, Clancy P, Bourke B, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J 2010; 159(2): 307-13.
127. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001. Circulation 2009; 119(16): 2202-8.
128. Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 2011; 98(3): 346-53.
129. McNally MM, Agle SC, Parker FM, Bogey WM, Powell CS, Stoner MC. Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair. J Vasc Surg 2010; 51(6): 1390-6.
130. Feeney JM, Burns K, Staff I, et al. Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm. J Am Coll Surg 2009; 209(1): 41-6.
131. Diehm N, Becker G, Katzen B, Benenati J, Kovacs M, Dick F. Statins are associated with decreased mortality in abdominal, but not in thoracic aortic aneurysm patients undergoing endovascular repair: propensity score-adjusted analysis. VASA 2008; 37(3): 241-9.
132. Kertai MD, Boersma E, Westerhout CM, et al. Reprinted article "A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery". Eur J Vasc Endovasc Surg 2011; 42 Suppl 1: S96-104.
133. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116(2): 96-103.
134. Kurzencwyg D, Filion KB, Pilote L, et al. Cardiac medical therapy among patients undergoing abdominal aortic aneurysm repair. Ann Vasc Surg 2006; 20(5): 569-76.
135. Leurs LJ, Visser P, Laheij RJ, Buth J, Harris PL, Blankensteijn JD. Statin use is associated with reduced all-cause mortality after endovascular abdominal aortic aneurysm repair. Vascular 2006; 14(1): 1-8.
136. Schouten O, Lever TM, Welten GM, et al. Long-term cardiac outcome in high-risk patients undergoing elective endovascular or open infrarenal abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2008; 36(6): 646-52.
137. Chaikof EL, Brewster DC, Dalman RL, et al. The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg 2009; 50(4 Suppl): S2-49.
138. Moll FL, Powell JT, Fraedrich G, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg 2011; 41 Suppl 1: S1-S58.
139. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nature medicine 2005; 11(12): 1330-8.
140. Yoshimura K, Aoki H, Ikeda Y, Furutani A, Hamano K, Matsuzaki M. Identification of c-Jun N-terminal kinase as a therapeutic target for abdominal aortic aneurysm. Ann NY Acad Sci 2006; 1085: 403-6.
141. Yoshimura K, Aoki H, Ikeda Y, Furutani A, Hamano K, Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase in mice. Ann NY Acad Sci 2006; 1085: 74-81.
142. Parodi FE, Mao D, Ennis TL, Bartoli MA, Thompson RW. Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. J Vasc Surg 2005; 41(3): 479-89.
143. Wang YX, Martin-McNulty B, da Cunha V, et al. Fasudil, a Rhokinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 2005; 111(17): 2219-26.
144. Aoki H, Yoshimura K, Matsuzaki M. Turning back the clock: regression of abdominal aortic aneurysms via pharmacotherapy. J Mol Med (Berl) 2007; 85(10): 1077-88.
145. Thompson RW. Aneurysm treatments expand. Nature medicine 2005; 11(12): 1279-81.
146. Shiraya S, Miwa K, Aoki M, et al. Hypertension accelerated experimental abdominal aortic aneurysm through upregulation of nuclear factor kappaB and Ets. Hypertension 2006; 48(4): 628-36.
147. Nakashima H, Aoki M, Miyake T, et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors. Circulation 2004; 109(1): 132-8.
148. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82(10): 1023-8.
149. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990; 10(5): 2327-34.
150. Satriano J, Schlondorff D. Activation and attenuation of transcription factor NF-kB in mouse glomerular mesangial cells in response to tumor necrosis factor-alpha, immunoglobulin G, and adenosine 3':5'-cyclic monophosphate. Evidence for involvement of reactive oxygen species. J Clin Invest 1994; 94(4): 1629-36.
151. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995; 91(7): 1914-7.
152. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 1995; 270(2): 933-43.
153. Bond M, Baker AH, Newby AC. Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and-3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999; 264(2): 561-7.
154. Takeshita H, Yoshizaki T, Miller WE, et al. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 1999; 73(7): 5548-55.
155. Kim H, Koh G. Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaBdependent pathway. Biochem Biophys Res Commun 2000; 269(2): 401-5.
156. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253(1-2): 269-85.
157. Davis V, Persidskaia R, Baca-Regen L, et al. Matrix Metalloproteinase-2 Production and Its Binding to the Matrix Are Increased in Abdominal Aortic Aneurysms. Arterioscler Thromb Vasc Biol 1998; 18(10): 1625-33.
158. Abisi S, Burnand KG, Waltham M, Humphries J, Taylor PR, Smith A. Cysteine protease activity in the wall of abdominal aortic aneurysms. J Vasc Surg 2007; 46(6): 1260-6.
159. Rizas KD, Ippagunta N, Tilson MD, 3rd. Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm. Cardiol Rev 2009; 17(5): 201-10.
160. Carrell TWG, Burnand KG, Wells GMA, Clements JM, Smith A. Stromelysin-1 (Matrix Metalloproteinase-3) and Tissue Inhibitor of Metalloproteinase-3 Are Overexpressed in the Wall of Abdominal Aortic Aneurysms. Circulation 2002; 105(4): 477-82.
161. Davis EC. Stability of elastin in the developing mouse aorta: a quantitative radioautographic study. Histochemistry 1993; 100(1): 17-26.
162. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000; 105(11): 1641-9.
163. Verma S, Lindsay TF. Regression of aortic aneurysms through pharmacologic therapy? The N Engl J Med 2006; 354(19): 2067-8.
164. Daugherty A, Cassis L. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2004; 24(3): 429-34.
165. Dollery CM, McEwan JR, Henney AM. Matrix Metalloproteinases and Cardiovascular Disease. Circ Res 1995; 77(5): 863-8.
166. Axisa B, Loftus IM, Naylor AR, et al. Prospective, Randomized, Double-Blind Trial Investigating the Effect of Doxycycline on Matrix Metalloproteinase Expression Within Atherosclerotic Carotid Plaques * Editorial Comment. Stroke 2002; 33(12): 2858-64.
167. McMillan WD, Patterson BK, Keen RR, Shively VP, Cipollone M, Pearce WH. In Situ Localization and Quantification of mRNA for 92-kD Type IV Collagenase and Its Inhibitor in Aneurysmal, Occlusive, and Normal Aorta. Arterioscler Thromb Vasc Biol 1995; 15(8): 1139-44.
168. McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999; 29(1): 122-7; discussion 7-9.
169. McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA, Pearce WH. Size Matters: The Relationship Between MMP-9 Expression and Aortic Diameter. Circulation 1997; 96(7): 2228-32.
170. Wassef M, Baxter BT, Chisholm RL, et al. Pathogenesis of abdominal aortic aneurysms: A multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg 2001; 34(4): 730-8.
171. Juvonen J, Juvonen T, Laurila A, et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997; 25(3): 499-505.
172. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996; 23(2): 336-46.
173. Kaito K, Urayama H, Watanabe G. Doxycycline treatment in a model of early abdominal aortic aneurysm. Surg Today 2003; 33(6): 426-33.
174. Thompson RW, Baxter BT. MMP Inhibition in Abdominal Aortic Aneurysms: Rationale for a Prospective Randomized Clinical Trial. Ann N Y Acad Sci 1999; 878(Inhibition of matrix metalloproteinases therapeutic applications): 159-78.
175. Liu J, Xiong W, Baca-Regen L, Nagase H, Baxter BT. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg 2003; 38(6): 1376-83.
176. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23(3): 483-8.
177. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: acomparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998; 28(6): 1082-93.
178. Huffman MD, Curci JA, Moore G, Kerns DB, Starcher BC, Thompson RW. Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms. Surgery 2000; 128(3): 429-38.
179. Prall AK, Longo GM, Mayhan WG, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 2002; 35(5): 923-9.
180. Sho E, Chu J, Sho M, et al. Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms. J Vasc Surg 2004; 39(6): 1312-21.
181. Franklin IJ, Harley SL, Greenhalgh RM, Powell JT. Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis. Br J Surg 1999; 86(6): 771-5.
182. Bartoli MA, Parodi FE, Chu J, et al. Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg 2006; 20(2): 228-36.
183. Curci JA, Mao D, Bohner DG, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31(2): 325-42.
184. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34(4): 606-10.
185. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002; 36(1): 1-12.
186. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009; 119(16): 2209-16.
187. Hackmann AE, Rubin BG, Sanchez LA, Geraghty PA, Thompson RW, Curci JA. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg 2008; 48(3): 519-26; discussion 26.
188. Meijer CA, Stijnen T, Wasser MN, Hamming JF, van Bockel JH, Lindeman JH. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med 2013; 159(12): 815-23.
189. Brophy CM, Reilly JM, Smith GJ, Tilson MD. The role of inflammation in nonspecific abdominal aortic aneurysm disease. Ann Vasc Surg 1991; 5(3): 229-33.
190. Newman KM, Jean-Claude J, Li H, Ramey WG, Tilson MD. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation 1994; 90(5 Pt 2): Ii224-7.
191. Shah PK. Inflammation, Metalloproteinases, and Increased Proteolysis: An Emerging Pathophysiological Paradigm in Aortic Aneurysm. Circulation 1997; 96(7): 2115-7.
192. Gregory AK, Yin NX, Capella J, Xia S, Newman KM, Tilson MD. Features of autoimmunity in the abdominal aortic aneurysm. Arch Surg 1996; 131(1): 85-8.
193. Ogata T, Gregoire L, Goddard KA, et al. Evidence for association between the HLA-DQA locus and abdominal aortic aneurysms in the Belgian population: a case control study. BMC Med Genet 2006; 7: 67.
194. Chan WL, Pejnovic N, Liew TV, Hamilton H. Predominance of Th2 response in human abdominal aortic aneurysm: Mistaken identity for IL-4-producing NK and NKT cells? Cell Immunol 2005; 233(2): 109-14.
195. Forester ND, Cruickshank SM, Scott DJA, Carding SR. Increased natural killer cell activity in patients with an abdominal aortic aneurysm. Br J Surg 2006; 93(1): 46-54.
196. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007; 117(11): 3359-68.
197. Sun J, Zhang J, Lindholt JS, et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 2009; 120(11): 973-82.
198. Platsoucas CD, Lu S, Nwaneshiudu I, et al. Abdominal Aortic Aneurysm Is a Specific Antigen-Driven T Cell Disease. Ann NY Acad Sci 2006; 1085 (The Abdominal Aortic Aneurysm: Genetics, Pathophysiology, and Molecular Biology): 224-35.
199. Galle C, Schandene L, Stordeur P, et al. Predominance of type 1 CD4+ T cells in human abdominal aortic aneurysm. Clin Exp Immunol 2005; 142(3): 519-27.
200. Treska V, Topolcan O, Pecen L. Cytokines as plasma markers of abdominal aortic aneurysm. Clinical chemistry and laboratory medicine: CCLM / FESCC 2000; 38(11): 1161-4.
201. Pagano MB, Zhou HF, Ennis TL, et al. Complement-dependent neutrophil recruitment is critical for the development of elastaseinduced abdominal aortic aneurysm. Circulation 2009; 119(13): 1805-13.
202. Tsuruda T, Kato J, Hatakeyama K, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008; 102(11): 1368-77.
203. Mayranpaa MI, Trosien JA, Fontaine V, et al. Mast cells associate with neovessels in the media and adventitia of abdominal aortic aneurysms. J Vasc Surg 2009; 50(2): 388-95; discussion 95-6.
204. Golledge J, Wolanski P, Parr A, Buttner P. Measurement and determinants of infrarenal aortic thrombus volume. Eur Radiol 2008; 18(9): 1987-94.
205. Touat Z, Ollivier V, Dai J, et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 2006; 168(3): 1022-30.
206. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 2008; 118(23): 2382-92.
207. Golledge J, Muller R, Clancy P, McCann M, Norman PE. Evaluation of the diagnostic and prognostic value of plasma Ddimer for abdominal aortic aneurysm. Eur Heart J 2011; 32(3): 354-64.
208. Dai J, Louedec L, Philippe M, Michel JB, Houard X. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model. J Vasc Surg 2009; 49(3): 719-27.
209. Karlsson L, Gnarpe J, Bergqvist D, Lindback J, Parsson H. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms--a prospective randomized double-blind trial. J Vasc Surg 2009; 50(1): 23-9.
210. Lindholt JS, Sorensen HT, Michel JB, Thomsen HF, Henneberg EW. Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovascular Surg 2008; 42(4): 329-34.
211. Golledge J, Kuivaniemi H. Genetics of abdominal aortic aneurysm. Curr Opin Cardiol 2013; 28(3): 290-6.
212. Maegdefessel L, Azuma J, Toh R, et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 2012; 122(2): 497-506.
213. Deux JF, Dai J, Riviere C, et al. Aortic aneurysms in a rat model: in vivo MR imaging of endovascular cell therapy. Radiology 2008; 246(1): 185-92.
214. Broz P, Ben-Haim N, Grzelakowski M, Marsch S, Meier W, Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. J Cardiovasc Pharmacol 2008; 51(3): 246-52.
215. Banciu M, Metselaar JM, Schiffelers RM, Storm G. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia (New York, NY) 2008; 10(2): 108-17.
216. Golledge J, Powell JT. Medical management of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2007; 34(3): 267-73.